21:34 , May 28, 2019 |  BC Extra  |  Financial News

May 28 Financial Quick Takes: Alphamab Oncology raises $60M; plus $180.5M for Panacea healthcare fund and more

Hudson Bay leads Alphamab Oncology's $60M series B Alphamab Oncology (Cayman) raised $60 million in a series B round led by Hudson Bay Capital, with participation from new investor and entrepreneur Adrian Cheng and existing...
13:30 , Dec 5, 2018 |  BC Innovations  |  Distillery Therapeutics

Hepatic

INDICATION: Non-alcoholic steatohepatitis (NASH) Patient sample and mouse studies suggest inhibiting the Notch pathway components HES1, γ secretase, MAML1 and NCSTN could help treat NASH. In NASH patient liver tissue samples, hepatocyte levels of HES1...
18:19 , Jun 15, 2018 |  BC Week In Review  |  Clinical News

Ayala reports Phase Ib data for AL101 in solid tumors

Ayala Pharmaceuticals Inc. (Rehovot, Israel) said once-weekly 4 mg IV AL101 (formerly BMS-906024) led to a complete response in a patient with gastroesophageal junction adenocarcinoma in a Phase Ib trial to treat locally advanced or...
19:34 , May 17, 2018 |  BC Innovations  |  Finance

Europe’s piece of the pie

With China’s rising infrastructure for life science innovation and the unabated growth of U.S. science, Europe has two cards to play that can help it compete globally: expertise in key core technologies and its centralized...
21:03 , Dec 8, 2017 |  BC Week In Review  |  Company News

Newco Ayala in-licenses BMS gamma secretase inhibitors

Bristol-Myers Squibb Co. (NYSE:BMY) granted newco Ayala Pharmaceuticals Inc. (Rehovot, Israel) exclusive, worldwide rights to BMS-906024 and BMS-986115. Ayala plans to develop the gamma secretase inhibitors as targeted treatments for cancers harboring specific Notch alterations....
22:07 , Dec 6, 2017 |  BC Extra  |  Company News

Newco Ayala in-licenses BMS gamma secretase inhibitors

Bristol-Myers Squibb Co. (NYSE:BMY) granted newco Ayala Pharmaceuticals Inc. (Rehovot, Israel) exclusive, worldwide rights to BMS-906024 and BMS-986115. Ayala plans to develop the gamma secretase inhibitors as targeted treatments for cancers harboring specific Notch alterations....
07:00 , Aug 1, 2013 |  BC Innovations  |  Targets & Mechanisms

Prostate cancer's nerves

In prostate cancer, a handful of companies are racing to develop third-generation antiandrogen therapeutics that overcome resistance mechanisms that render first- and second-generation molecules ineffective. 1,2 The problem is that any direct attack on the...
07:00 , Jul 25, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Melanoma E2F transcription factor 1 (E2F1); tumor protein p73 (TP73; p73) Cell culture and mouse studies suggest combining methotrexate with an antifolate prodrug could help...
07:00 , Apr 2, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Infectious disease

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Infectious disease Sepsis Programmed cell death 1 (PDCD1; PD-1; CD279) Studies in mice and in vitro studies in murine macrophages suggest that...
08:00 , Jan 14, 2008 |  BC Week In Review  |  Company News

Samaritan board of directors update

Samaritan Pharmaceuticals Inc. (OTCBB:LIV), Las Vegas, Nev.   Business: Infectious, Neurology, Cancer   Appointed: Jack Ayala, EVP and chief administrative officer at Palm Springs General Hospital; and Robert Crane, founder of Retirement Planning Consultants Inc....